

FOR MORE INFORMATION:

**Company Contact:**  
Jill C Blumhoff  
Chief Financial Officer  
Phone: 765.497.8381  
[jblumhoff@BASinc.com](mailto:jblumhoff@BASinc.com)

## **BASi Launches Embrace Automation Grant Program with Culex NxT™ Automated Blood Sampling System**

**WEST LAFAYETTE, IN** – August 25, 2016 -- **Bioanalytical Systems, Inc. (BASi) (NASDAQ:BASI)**, a recognized global leader in the development of instrumentation for automated blood sampling in animal models, is proud to announce its launch of the Embrace Automation grant program featuring the BASi Culex NxT™ Automated Blood Sampling system and Return™.

As laboratory techniques and instrumentation evolved, many formerly manual processes became automated—from basic pipetting to intricate high-throughput screening. In vivo studies are no different. BASi Culex® Automated Blood Sampling systems deliver programmable, continuous automated blood micro sampling, thus providing a full pharmacokinetic curve from a single, fully conscious, freely moving animal. The system allows for the simultaneous collection of multiple data streams such as blood, bile, metabolites, dialysates and more from species as small as mice and as large as swine. Researchers around the globe have been screening compounds and generating high quality data from less stressed animal models with minimal handling by technicians using the BASi Culex® system and accessories for nearly two decades. However, many researchers still labor through in vivo drug discovery studies manually and now have the opportunity to experience an automated platform at no cost for a thirty-day period.

With BASi's Embrace Automation grant program, researchers are provided with a BASi Culex NxT ABC-R™, four catheterized animals, consumables to run studies, and full training and support for the instruments.

Jacqueline Lemke, President and Chief Executive Officer of BASi, commented, “BASi is proud to launch this exciting Embrace Automation Culex® grant program. We know that the in vivo sampling systems provide better data with less stressed animals, save time and create efficiencies by using fewer animal models and less technician time when running pharmacokinetic and pharmacodynamic studies. This program gives our customers a free trial to see first-hand the benefits of automated sampling. Feedback received from customers in the program thus far has been very positive and often resulted in conversion to automation. BASi has multiple large pharmaceutical companies and academic research facilities globally enjoying the benefits of our technology. With the BASi Embrace Automation Program, we want to give all researchers a chance to experience the innovation that they need to generate better data, using less animals and at lower costs than the still highly used manual techniques. Better data, saving lives, saving time and saving money is the BASi Culex® difference.”

For more information on how to get your laboratory enrolled in our Embrace Automation grant program, please contact Gloria Holbrook, BASi Culex® Product Development Manager, at 765-237-7796, or Shelly Carballo, BASi Business Development, at 765-418-4384. You can also visit [www.basinc.com/products/embrace](http://www.basinc.com/products/embrace) for program information.



## **About Bioanalytical Systems, Inc.**

BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. BASi is recognized globally for expertise in automated blood sampling instruments has been manufacturing these instruments and accessories for over 40 years. BASi focuses on developing innovative products that increase efficiency and reduce the cost of taking new drugs to market. Visit [www.BASinc.com](http://www.BASinc.com) for more information about BASi.

*This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.*